🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Insulet appoints new CFO to bolster leadership team

EditorEmilio Ghigini
Published 03/20/2024, 06:10 AM
© Reuters.

ACTON, Mass. - Insulet (NASDAQ:PODD) Corporation (NASDAQ: PODD), a leading medical device company known for its tubeless insulin pump technology, announced the appointment of Ana Maria Chadwick as its new Executive Vice President, Chief Financial Officer, and Treasurer, set to take effect on April 22, 2024. This move concludes a comprehensive search by the company to fill the executive role.

Ana Maria Chadwick, who will be leaving her current role as Executive Vice President and CFO of Pitney Bowes (NYSE:PBI), brings over 30 years of experience in finance and operations to Insulet. Her tenure at GE, spanning more than 27 years, saw her in various leadership positions, including CEO and COO of GE Capital Global Legacy Solutions and CFO of GE Capital Energy Financial Services.

Jim Hollingshead, President and CEO of Insulet, expressed confidence in Chadwick's capabilities, emphasizing her track record as a versatile and accomplished executive with a deep understanding of capital markets, business strategy, and investor relations.

Chadwick's career has been marked by her leadership in financial reporting and her efforts to drive financial and operational efficiencies across the U.S., Latin America, and Europe. Her expertise extends to a comprehensive grasp of tax policy and business strategy.

In addition to her corporate roles, Chadwick is actively involved in governance and mentorship, serving on the board of directors for Dollar General (NYSE:DG) and LiveGirl, Inc., and chairing the Audit Committee and the Pitney Bowes ILC Bank in Utah.

Lauren Budden, who has been serving as Insulet's Interim CFO and Treasurer, will continue with the company as Group Vice President, Chief Accounting Officer, and Controller. Hollingshead thanked Budden for her exceptional leadership during the transition period.

Insulet, headquartered in Massachusetts, continues to innovate in the medical device sector with its Omnipod product platform, aiming to simplify the lives of people with diabetes through advanced insulin delivery systems. The company's flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors and can be managed via smartphone or controller.

The information in this article is based on a press release statement from Insulet Corporation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.